Back to Agenda
Integration of Manufacturing Quality Assessment and Pre-Approval Inspections
Session Chair(s)
Joanne Wang, PHD
Acting Branch Chief, OPMA, OPQ, CDER, FDA, United States
This session will discuss various case studies that illustrate the mechanism for risk-based holistic assessment of pharmaceutical manufacturing, and how such assessment leads to a thorough and timely assessment.
Learning Objective : Describe the benefits of holistic pharmaceutical manufacturing assessment that involves closer alliance between drug product quality assessment and facility inspection; Recognize manufacturing risks that act as triggers for pre approval inspections.
Speaker(s)
Integrated CMC Review and Inspection for a Combination Product: A Case Study
Executive VP, RSD Global Consulting, Clinipace, United States
Proposal to Improve Risk-Based Regulatory Application Assessment
Vice President, Head of Global CMC, Pfizer Inc, United States
Regulatory Considerations for Manufacturing Assessment and Pre-Approval Inspections
Director, Div of Inspectional Assessment, OPF, OPQ, CDER, FDA, United States
Have an account?